Yoon‐Koo Kang

Ulsan College

Publishes on Gastric Cancer Management and Outcomes, Gastrointestinal Tumor Research and Treatment, Colorectal Cancer Treatments and Studies. 865 papers and 60.7k citations.

🌟#2 All-Time Leader in HER2· PubIndex 90

865Publications

60.7kTotal Citations

#2in HER2

Gastric Cancer Management and Outcomes Gastrointestinal Tumor Research and Treatment Colorectal Cancer Treatments and Studies Hepatocellular Carcinoma Treatment and Prognosis Cancer Immunotherapy and Biomarkers

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Yung‐Jue Bang, Eric Van Cutsem, A. Feyereislova et al.|The Lancet|2010

Cited by 7.3kOpen Access

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen et al.|The Lancet Oncology|2008

Cited by 5.8k

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau et al.|The Lancet|2017

Cited by 4.3kOpen Access

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Narikazu Boku, Taroh Satoh et al.|The Lancet|2017

Cited by 2.3kOpen Access

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen et al.|The Lancet Oncology|2019

Cited by 1.6k

Similar Researchers

Coming soon — researchers in similar fields and career stages